BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38834293)

  • 1. Validation of the BOADICEA model in a prospective cohort of
    Yang X; Mooij TM; Leslie G; Ficorella L; Andrieu N; Kast K; Singer CF; Jakubowska A; van Gils CH; Tan YY; Engel C; Adank MA; van Asperen CJ; Ausems MGEM; Berthet P; ; Collee MJ; Cook JA; Eason J; Spaendonck-Zwarts KYV; Evans DG; Gómez García EB; Hanson H; Izatt L; Kemp Z; Lalloo F; Lasset C; Lesueur F; Musgrave H; Nambot S; Noguès C; Oosterwijk JC; Stoppa-Lyonnet D; Tischkowitz M; Tripathi V; Wevers MR; Zhao E; van Leeuwen FE; Schmidt MK; Easton DF; Rookus MA; Antoniou AC
    J Med Genet; 2024 Jun; ():. PubMed ID: 38834293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study.
    Yang X; Eriksson M; Czene K; Lee A; Leslie G; Lush M; Wang J; Dennis J; Dorling L; Carvalho S; Mavaddat N; Simard J; Schmidt MK; Easton DF; Hall P; Antoniou AC
    J Med Genet; 2022 Dec; 59(12):1196-1205. PubMed ID: 36162852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 10-year performance of four models of breast cancer risk: a validation study.
    Terry MB; Liao Y; Whittemore AS; Leoce N; Buchsbaum R; Zeinomar N; Dite GS; Chung WK; Knight JA; Southey MC; Milne RL; Goldgar D; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; Andrulis IL; John EM; Phillips KA; Daly MB; Buys SS; Hopper JL; MacInnis RJ
    Lancet Oncol; 2019 Apr; 20(4):504-517. PubMed ID: 30799262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population frequencies of pathogenic alleles of BRCA1 and BRCA2: analysis of 173 Danish breast cancer pedigrees using the BOADICEA model.
    Terkelsen T; Christensen LL; Fenton DC; Jensen UB; Sunde L; Thomassen M; Skytte AB
    Fam Cancer; 2019 Oct; 18(4):381-388. PubMed ID: 31435815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium.
    Fischer C; Kuchenbäcker K; Engel C; Zachariae S; Rhiem K; Meindl A; Rahner N; Dikow N; Plendl H; Debatin I; Grimm T; Gadzicki D; Flöttmann R; Horvath J; Schröck E; Stock F; Schäfer D; Schwaab I; Kartsonaki C; Mavaddat N; Schlegelberger B; Antoniou AC; Schmutzler R;
    J Med Genet; 2013 Jun; 50(6):360-7. PubMed ID: 23564750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polygenic risk scores indicate extreme ages at onset of breast cancer in female BRCA1/2 pathogenic variant carriers.
    Borde J; Laitman Y; Blümcke B; Niederacher D; Weber-Lassalle K; Sutter C; Rump A; Arnold N; Wang-Gohrke S; Horváth J; Gehrig A; Schmidt G; Dutrannoy V; Ramser J; Hentschel J; Meindl A; Schroeder C; Wappenschmidt B; Engel C; Kuchenbaecker K; Schmutzler RK; Friedman E; Hahnen E; Ernst C
    BMC Cancer; 2022 Jun; 22(1):706. PubMed ID: 35761208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing the BOADICEA cancer risk prediction model to incorporate new data on
    Lee A; Mavaddat N; Cunningham A; Carver T; Ficorella L; Archer S; Walter FM; Tischkowitz M; Roberts J; Usher-Smith J; Simard J; Schmidt MK; Devilee P; Zadnik V; Jürgens H; Mouret-Fourme E; De Pauw A; Rookus M; Mooij TM; Pharoah PP; Easton DF; Antoniou AC
    J Med Genet; 2022 Dec; 59(12):1206-1218. PubMed ID: 36162851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes.
    Gallagher S; Hughes E; Wagner S; Tshiaba P; Rosenthal E; Roa BB; Kurian AW; Domchek SM; Garber J; Lancaster J; Weitzel JN; Gutin A; Lanchbury JS; Robson M
    JAMA Netw Open; 2020 Jul; 3(7):e208501. PubMed ID: 32609350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.
    Antoniou AC; Hardy R; Walker L; Evans DG; Shenton A; Eeles R; Shanley S; Pichert G; Izatt L; Rose S; Douglas F; Eccles D; Morrison PJ; Scott J; Zimmern RL; Easton DF; Pharoah PD
    J Med Genet; 2008 Jul; 45(7):425-31. PubMed ID: 18413374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis.
    van Bommel MHD; IntHout J; Veldmate G; Kets CM; de Hullu JA; van Altena AM; Harmsen MG
    Hum Reprod Update; 2023 Mar; 29(2):197-217. PubMed ID: 36383189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association and performance of polygenic risk scores for breast cancer among French women presenting or not a familial predisposition to the disease.
    Jiao Y; Truong T; Eon-Marchais S; Mebirouk N; Caputo SM; Dondon MG; Karimi M; Le Gal D; Beauvallet J; Le Floch É; Dandine-Roulland C; Bacq-Daian D; Olaso R; Albuisson J; Audebert-Bellanger S; Berthet P; Bonadona V; Buecher B; Caron O; Cavaillé M; Chiesa J; Colas C; Collonge-Rame MA; Coupier I; Delnatte C; De Pauw A; Dreyfus H; Fert-Ferrer S; Gauthier-Villars M; Gesta P; Giraud S; Gladieff L; Golmard L; Lasset C; Lejeune-Dumoulin S; Léoné M; Limacher JM; Lortholary A; Luporsi É; Mari V; Maugard CM; Mortemousque I; Mouret-Fourme E; Nambot S; Noguès C; Popovici C; Prieur F; Pujol P; Sevenet N; Sobol H; Toulas C; Uhrhammer N; Vaur D; Venat L; Boland-Augé A; Guénel P; Deleuze JF; Stoppa-Lyonnet D; Andrieu N; Lesueur F
    Eur J Cancer; 2023 Jan; 179():76-86. PubMed ID: 36509001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry.
    Pal Choudhury P; Brook MN; Hurson AN; Lee A; Mulder CV; Coulson P; Schoemaker MJ; Jones ME; Swerdlow AJ; Chatterjee N; Antoniou AC; Garcia-Closas M
    Breast Cancer Res; 2021 Feb; 23(1):22. PubMed ID: 33588869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probability estimation models for prediction of BRCA1 and BRCA2 mutation carriers: COS compares favourably with other models.
    Roudgari H; Miedzybrodzka ZH; Haites NE
    Fam Cancer; 2008; 7(3):199-212. PubMed ID: 18097771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.
    Antoniou AC; Cunningham AP; Peto J; Evans DG; Lalloo F; Narod SA; Risch HA; Eyfjord JE; Hopper JL; Southey MC; Olsson H; Johannsson O; Borg A; Pasini B; Radice P; Manoukian S; Eccles DM; Tang N; Olah E; Anton-Culver H; Warner E; Lubinski J; Gronwald J; Gorski B; Tryggvadottir L; Syrjakoski K; Kallioniemi OP; Eerola H; Nevanlinna H; Pharoah PD; Easton DF
    Br J Cancer; 2008 Apr; 98(8):1457-66. PubMed ID: 18349832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in
    Yadav S; Boddicker NJ; Na J; Polley EC; Hu C; Hart SN; Gnanaolivu RD; Larson N; Holtegaard S; Huang H; Dunn CA; Teras LR; Patel AV; Lacey JV; Neuhausen SL; Martinez E; Haiman C; Chen F; Ruddy KJ; Olson JE; John EM; Kurian AW; Sandler DP; O'Brien KM; Taylor JA; Weinberg CR; Anton-Culver H; Ziogas A; Zirpoli G; Goldgar DE; Palmer JR; Domchek SM; Weitzel JN; Nathanson KL; Kraft P; Couch FJ
    J Clin Oncol; 2023 Mar; 41(9):1703-1713. PubMed ID: 36623243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of BRCA1/2 mutation prediction models in male breast cancer patients.
    Moghadasi S; Grundeken V; Janssen LAM; Dijkstra NH; Rodríguez-Girondo M; van Zelst-Stams WAG; Oosterwijk JC; Ausems MGEM; Oldenburg RA; Adank MA; Blom EW; Ruijs MWG; van Os TAM; van Deurzen CHM; Martens JWM; Schroder CP; Wijnen JT; Vreeswijk MPG; van Asperen CJ
    Clin Genet; 2018 Jan; 93(1):52-59. PubMed ID: 28589637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors.
    Lee A; Yang X; Tyrer J; Gentry-Maharaj A; Ryan A; Mavaddat N; Cunningham AP; Carver T; Archer S; Leslie G; Kalsi J; Gaba F; Manchanda R; Gayther S; Ramus SJ; Walter FM; Tischkowitz M; Jacobs I; Menon U; Easton DF; Pharoah P; Antoniou AC
    J Med Genet; 2022 Jul; 59(7):632-643. PubMed ID: 34844974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial.
    Archer S; Fennell N; Colvin E; Laquindanum R; Mills M; Dennis R; Stutzin Donoso F; Gold R; Fan A; Downes K; Ford J; Antoniou AC; Kurian AW; Evans DG; Tischkowitz M
    Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporating tumour pathology information into breast cancer risk prediction algorithms.
    Mavaddat N; Rebbeck TR; Lakhani SR; Easton DF; Antoniou AC
    Breast Cancer Res; 2010; 12(3):R28. PubMed ID: 20482762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.